Form 8-K - Current report:
SEC Accession No. 0001140361-25-031008
Filing Date
2025-08-14
Accepted
2025-08-14 06:26:15
Documents
14
Period of Report
2025-08-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20053941_8k.htm   iXBRL 8-K 35743
2 EXHIBIT 99.1 ef20053941_ex99-1.htm EX-99.1 22644
6 image.jpg GRAPHIC 1885
  Complete submission text file 0001140361-25-031008.txt   197332

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aqst-20250813.xsd EX-101.SCH 3868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aqst-20250813_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aqst-20250813_pre.xml EX-101.PRE 16046
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20053941_8k_htm.xml XML 4067
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 251214098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)